On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $32.15 which represents a slight increase of $1.81 or 5.97% from the prior close of $30.34. The stock opened at ...

Canaccord raised the firm’s price target on Hims & Hers to $38 from $28 and keeps a Buy rating on the shares. The stock rallied 70% in ...

Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.

Hims & Hers' financials are robust, with strong and accelerating revenue growth, growing free cash flow, manageable SBC, and ...

Hims & Hers achieved a 44% YoY increase in Q3 2024, surpassing 2 million active users. Find out what positions HIMS as a key ...

Hims & Hers Health (HIMS) has soared after Hunterbrook Media says that the company could benefit from President-elect Donald ...

On Wednesday, Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $30.34 which represents a decrease of $-0.34 or -1.11% from the prior close of $30.68. The stock opened at $31.49 and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Shares of Hims & Hers are moving higher after President-elect Donald Trump nominated Dr. Marty Makary, a pancreatic surgeon at Johns ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) has received a consensus rating of “Hold” from the sixteen analysts ...

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that Hims & ...